Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

RET rivals Loxo and Blueprint face off with early-stage data

No clear winner between RET inhibitor rivals

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

The power of video

Video is not a new marketing channel. Compared to the realms of augmented and virtual reality it’s been around for donkey’s years. And yet video has continued to grow in...

Page & Page Health

- PMLiVE

Lucid’s Big Fat Charity Pub Quiz

Last week Lucid SPIRIT held the first ever Lucid Big Fat Charity Pub Quiz to raise money for our charity partner, Wycombe Homeless Connection (WHC).There were fabulous prizes to be...

Lucid Group Communications Limited

- PMLiVE

China: AstraZeneca’s new engine for growth and innovation

AstraZeneca’s Mark Mallon talks to PME about how its long-term investment in China is paying off

Medtech’s mixed-up monsters

Conglomerate medtechs only make sense in the light of evolution

- PMLiVE

KAM 2.0

Elevating Key Account Management beyond country limits

- PMLiVE

Chinese biotech’s global ambitions

BeiGene aims to be the first home-grown big biopharma

- PMLiVE

Roche gets wider approval for haemophilia drug Hemlibra

Approved to treat bleeding episodes in patients without inhibitors

Insights from the charity sector

Insights from the charity sector – from patient engagement to people-driven design

Marianne Guldbrandsen, Strategy Director at Cuttsy+Cuttsy and former Head of Innovation and Strategic Partnerships at Macmillan, discusses how people-driven research leads to truly patient-centred products and services, and what the...

Cuttsy + Cuttsy

- PMLiVE

Three share Nobel chemistry prize for work on protein ‘evolution’

Frances Arnold becomes the fifth woman ever to be awarded in chemistry

- PMLiVE

Leadiant gets FDA OK for bubble boy disease drug

New therapy will rival Orchard's Strimvelis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links